Randomized trial · people
Abaloparatide: normal bone biopsies after up to 18 months in ACTIVE
Checked against the paper Randomized trialPublished by PepVault
The takeaway
For abaloparatide users, this adds tissue-level evidence that up to 18 months of treatment in ACTIVE did not raise bone safety concerns in biopsies.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2017
- Journal
- Bone
What they tested
The team wanted to know how daily abaloparatide shots affect the look and makeup of bone tissue when viewed under a microscope.
How the study was done
A biopsy substudy of the phase 3 ACTIVE randomized trial in people being treated for osteoporosis. Participants got blinded daily shots under the skin of abaloparatide 80μg/d or placebo (a dummy shot), or open-label teriparatide 20μg/d, for 18 months, with hip bone (iliac crest) biopsies taken between months 12 and 18.

What they found
Bone samples from the abaloparatide group showed normal bone structure, with no signs of harm to how bone mineralized or to how new layered bone formed. There were no marrow problems, no marrow scarring (fibrosis), and no excess unmineralized bone (osteoid) or disorganized woven bone. Across the three groups, most standard bone tissue measures differed little: eroded surface, a sign of bone breakdown, was lower with abaloparatide than with placebo, while cortical porosity, the amount of space in the outer bone shell, was higher with both abaloparatide and teriparatide than with placebo.
What it doesn’t show
This is a biopsy substudy using bone from one site, the iliac crest, so it speaks to bone tissue under the microscope rather than to fracture risk. The teriparatide comparison group was open-label, not blinded.
The paper
Moreira et al. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial. Bone. 2017.
The compound
More studies on Abaloparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Abaloparatide raised hip BMD around a virtual hip stem in ACTIVERandomized trial · people · 2024
- Abaloparatide improved hip geometry vs placebo in ACTIVE-JRandomized trial · people · 2023
- Abaloparatide then alendronate: 84% lower vertebral fracture riskRandomized trial · people · 2018
- Abaloparatide: fewer new vertebral fractures vs placebo in ACTIVERandomized trial · people · 2016
- Every study on Abaloparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.